Microsatellite Instability (MSI) characterization has been routinely performed for almost two decades to
identify genomic instability associated with Lynch Syndrome. Recently, MSI testing has expanded to
become a pan tumor biomarker associated with response to immune checkpoint inhibitors.
In Session 1 of the Virtual Microsatellite Instability (MSI) Series, our speakers will discuss:
Dr. Jeff Bacher is a Senior Scientist at Promega and has been involved in research and development of microsatellite markers and tests for MSI for over 20 years. He was the lead scientist responsible for development of Promega’s first and second generation MSI kits, and more recently has been investigating the utility of using expanded marker panels and new technologies to further improve performance of MSI testing for all types of cancers and liquid biopsies.
Dr. James Eshleman received his MD and PhD in cell biology from the University of Pennsylvania in 1988. Following an internship in Internal Medicine, he completed Clinical Pathology training at the University of Pennsylvania. He then completed a post-doctoral fellowship with Dr. Sandy Markowitz at Case Western Reserve University where they demonstrated that microsatellite (MSI) unstable colon cancers have a mutator phenotype with elevated mutation rates of both base substitutions and frameshift mutations. He joined the faculty at Johns Hopkins in 1997, where his research has focused on MSI detection, molecular diagnosis of pancreatic cancer, and novel therapeutics of cancer. In collaboration with Drs. Dung Le and Luis Diaz, they demonstrated that patients with mismatch repair defective (MMRd)/MSI cancers produce T-cell responses to mutation-associated neo-antigens (MANA's) and respond to immunotherapy. He has authored over 150 peer-reviewed publications, has received the AACR team science award for pancreatic cancer whole exome sequencing, and multiple teaching awards.
Heather Hampel is a Professor in the Department of Internal Medicine and Associate Director of the Division of Human Genetics. She coordinated the Columbus-area Lynch syndrome study that determined the frequency of Lynch syndrome among newly diagnosed patients with these cancers. She is the PI of the Ohio Colorectal Cancer Prevention, a statewide study to identify patients with hereditary cancer syndromes and provide cascade testing to their at-risk family members. Heather was the Region IV Representative on the Board of Directors of the National Society of Genetic Counselors in 2003–2004. She was on the Board of Directors for the American Board of Genetic Counseling from 2006–2011, serving as President in 2009 and 2010. She has been on the Steering Committee of the National Colorectal Cancer Roundtable since 2016. She was on the Council of the Collaborative Group of the Americas on Inherited Colorectal Cancer from 2016–2019, serving as president in 2017-2018. She was just elected Secretary/Treasurer Elect of the National Society of Genetic Counselors with her term starting in 2021.
Dr. Gerry Blobe is a Professor of Medicine, Pharmacology and Cancer Biology at Duke University School of Medicine. He is currently the Associate Director of Training and Education for the Duke Cancer Institute. Dr. Blobe’s laboratory at Duke University investigates the role of TGF-β superfamily signaling in cancer biology, focusing on mechanisms for their dichotomous tumor promoting and suppressing function, as well as investigating strategies for targeting these pathways. His research has established novel paradigms for TGF-β co-receptor function in regulating the trafficking and signaling of associated receptors, as well as the role of these TGF-β co-receptors in cancer biology. Clinically he specializes in treatment of patients with colorectal and pancreatic cancer, and in Phase I therapeutics. Dr. Blobe’s lab has received peer-reviewed funding from the National Institutes of Health/National Cancer Institute, the Department of Defense, the American Cancer Society and the American Heart Association. Dr. Blobe has served as an Associate Editor for The Journal of Clinical Investigation, on the editorial board for The Journal of Biological Chemistry, and as a standing member of the NIH Molecular Oncology Study Section. For his research efforts, Dr. Blobe has been awarded a V Foundation Scholar Award, a Research Scholar Award from the American Cancer Society, the 2005 Gertrude B. Elion Award for Cancer Research from the American Association for Cancer Research and was inducted into the American Society of Clinical Investigation.
The speakers below have been approved for Continuing Education Credits. To redeem your credits, locate the presentation you watched and click on the CE buttons for further direction. For more general information regarding continuing education, the processes to receive credits, and the accreditation bodies, Click here
|Operating System||Internet Explorer||Firefox||Chrome||Safari|
|Windows 7||IE8+||FF10+||Chrome15+||Windows 8||IE10||FF10+||Chrome15+|
|Mac OS X||FF10+||Chrome15+||Safari5.1+|
- For viewing Webinars:
- For viewing Virtual Events